ATE387217T1 - Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen - Google Patents

Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen

Info

Publication number
ATE387217T1
ATE387217T1 AT03077205T AT03077205T ATE387217T1 AT E387217 T1 ATE387217 T1 AT E387217T1 AT 03077205 T AT03077205 T AT 03077205T AT 03077205 T AT03077205 T AT 03077205T AT E387217 T1 ATE387217 T1 AT E387217T1
Authority
AT
Austria
Prior art keywords
mannose
muscle cells
phosphate receptor
gene transfer
mediated gene
Prior art date
Application number
AT03077205T
Other languages
English (en)
Inventor
Gerard Johannes Platenburg
Original Assignee
Lbr Medbiotech B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lbr Medbiotech B V filed Critical Lbr Medbiotech B V
Application granted granted Critical
Publication of ATE387217T1 publication Critical patent/ATE387217T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT03077205T 2003-07-11 2003-07-11 Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen ATE387217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03077205A EP1495769B1 (de) 2003-07-11 2003-07-11 Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen

Publications (1)

Publication Number Publication Date
ATE387217T1 true ATE387217T1 (de) 2008-03-15

Family

ID=33442814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03077205T ATE387217T1 (de) 2003-07-11 2003-07-11 Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen

Country Status (5)

Country Link
EP (1) EP1495769B1 (de)
AT (1) ATE387217T1 (de)
DE (1) DE60319354T2 (de)
DK (1) DK1495769T3 (de)
ES (1) ES2302898T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
GB0524987D0 (en) 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (de) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
EP2049664B1 (de) 2006-08-11 2011-09-14 Prosensa Technologies B.V. Einzelsträngige Oligonukleotide, welche komplementär zu repetitiven Elementen sind, zur Behandlung von DNS-Wiederholungen-Instabilitäts-assoziierten Erkrankungen
WO2009008725A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
NZ582521A (en) 2007-07-12 2011-09-30 Prosensa Technologies Bv A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
CN102203253B (zh) 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
WO2010123369A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
ES2576853T3 (es) 2009-07-03 2016-07-11 Inserm - Institut National De La Santé Et De La Recherche Médicale Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes
KR102113306B1 (ko) 2009-11-12 2020-05-21 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
CN104203289B (zh) 2012-01-27 2020-11-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CN104918639B (zh) * 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的***
CN104884618A (zh) 2012-11-15 2015-09-02 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合物
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
EA035882B1 (ru) 2013-03-14 2020-08-27 Сарепта Терапьютикс, Инк. Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
WO2014144978A2 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
UA127432C2 (uk) 2016-03-14 2023-08-23 Ф. Хоффманн-Ля Рош Аг Олігонуклеотид для зниження експресії pd-l1
CN113474633A (zh) 2019-02-26 2021-10-01 罗氏创新中心哥本哈根有限公司 寡核苷酸配制方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups

Also Published As

Publication number Publication date
DK1495769T3 (da) 2008-06-23
DE60319354T2 (de) 2009-03-26
ES2302898T3 (es) 2008-08-01
DE60319354D1 (de) 2008-04-10
EP1495769B1 (de) 2008-02-27
EP1495769A1 (de) 2005-01-12

Similar Documents

Publication Publication Date Title
ATE387217T1 (de) Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen
EP1191098A3 (de) Pharmazeutische Zusammensetzung zur Behandlung von Duchenne-Muskeldystrophie
EP3284823A3 (de) Verfahren für effizientes exon-(44)-skipping bei duchenne-muskeldystrophie und zugehörige mittel
EP2206781A3 (de) Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon
JP2005500025A5 (de)
IL164637A0 (en) Vaginal care compositions containing viable microorganisms
WO2007125429A3 (en) Method for the synthesis of triazole- containing oligonucleotide derivatives
GB0307803D0 (en) Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
DK1756259T3 (da) Reaktorsystem med omrørt beholder
ATE391134T1 (de) Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
WO2008078190A3 (en) Compounds for fluorescence imaging
IL186139A0 (en) Epidermal growth factor receptor gene copy number
EP1671998A3 (de) Verfahren zur Herstellung von Komponenten mit Indolocarbazol-Gruppen
Kiviniemi et al. Synthesis of aminoglycoside-3′-conjugates of 2′-O-methyl oligoribonucleotides and their invasion to a 19F labeled HIV-1 TAR model
EP1736501A4 (de) Peg-funktionelles nucleinsäurekonjugat
Lundin et al. Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored “Bioplex” formation
IL149599A0 (en) Use of disease-associated gene
Hu et al. Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy) phenyl] pyrrolocytosine
Khim et al. Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors
WO2005072053A9 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
EP1129725A3 (de) Oligonukleotid-Konjugate
JP2003508618A5 (de)
AU2002367785A8 (en) Allosteric nucleic acid sensor molecules
EP1689447A4 (de) Gentransfer zur regulierung des tonus der glatten muskulatur
Bielecki et al. Świadomość zasad zapobiegania chorobom układu krążenia w populacji dorosłych mieszkańców Polski. Wyniki programu WOBASZ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties